In both groups of patients, biomarkers associated with improved RFS and OS were represented by higher levels of tumor mutational burden, tumor PD-L1, intratumoral CD8+ T cells and IFN-γ-associated gene signatures, and lower levels of serum C-reactive protein [53]. The gene discussed is CD8A; the disease is neoplasm.